Outcome of Women With Cervical Cancer

NCT02026648 | Completed

• 1 other identifier: 102159-E
• Study Type: observational
• Target: 81
• Locations: 1 country
• Sites: 1

Brief Summary

Squamous cell carcinoma (SCC) of the cervix has showed a marked decline in developed countries over the past 40 years, however, there has also been an increase in relative and absolute incidence of adenocarcinoma and adenosquamous carcinoma (AC) of the uterine cervix over the same period. Our understanding of the natural history and optimal management of AC is limited. It appears that AC and SCC of the cervix behave differently. They are different in epidemiology, prognostic factors, and patterns of failure after similar treatments. Available data suggest that they may also differ in their response to treatment. We postulate that new treatment strategies specifically tailored to AC should be explored. However, there is few data about outcome of cervical cancer in Taiwan. So we propose this proposal for retrospective analysis of clinicopathological parameters and outcomes in patients of cervical cancer, especially for cervical adenocarcinoma and adenosquamous carcinoma.

Conditions

Cervical Cancer

Outcome Measures

Primary Outcomes (1)

• Outcome of women with cervical cancer

  20 years

Study Arms (1)

cases with cervical cancer

Eligibility Criteria

• Age: 20 Years - 99 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

the cases with cervical cancer

You may qualify if:

• Time interval: from 1991 to date.
• Comprehensive surgical staging, debulking procedure, radiotherapy or chemotherapy.
• All female patients with cervical cancer who underwent treatment for cervical cancer at Far Eastern Memorial Hospital.
• All the patients diagnosed as cervical cancer, especially for women with adeno- and adenosquamous carcinoma.
• To review:
• Clinical data: including age at diagnosis, presenting symptoms, gravidity, parity, menstrual history, body mass index, history of diabetes, hypertension, personal history of cancer and staging.
• Pathologic information: deep stromal invasion, lymph-vascular space invasion, lymph node involvement, parametrium invasion, vaginal cut end and tumor size.
• Survival data: disease-free and overall survival.
• Radiation report, Chemotherapy treatment, operation, discharge and admission note.

You may not qualify if:

• Not comprehensive staging/debulking procedure.
• Patients who died of postoperative complications within 30 days after surgery were excluded from the survival analysis.
• Female minors or disabled persons.

Sponsors & Collaborators

• Far Eastern Memorial Hospital: lead

Study Sites (1)

Far Eastern Memorial Hospital

Banqiao District, Taipei, 22050, Taiwan

Location

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief, Department of Obstetrics & Gynecology

Study Record Dates

• First Submitted: January 1, 2014
• First Posted: January 3, 2014
• Study Start: January 1, 2014
• Primary Completion: November 1, 2015
• Study Completion: May 1, 2016
• Last Updated: September 7, 2016

Record last verified: 2016-02

Locations

TW (1)